SLE全身性紅斑性狼瘡
| dsDNA |
30-90 % |
| Nucleosomes |
40-70 % |
| Histones |
50-80 % |
| U1-nRNP |
15-40 % |
| Sm |
5-30 % |
| SS-A (Ro) |
20-60 % |
| SS-B (La) |
10-20 % |
| Cyclin I (PCNA) |
3 % |
| Ku |
5-20 % |
| Ribosomal P |
20-40 % |
| Cardiolipin、β2-GP1 |
5-10 % |
Progressive Systemic Sclerosis (diffuse form)
| 自體抗體 |
盛行率 |
| SSDNA |
30-60 % |
| Fibrillar in (U3-nRNP) |
5-10 % |
| PM-Scl |
3 % |
| Sc1 -70 |
25-75 % |
| RNA Polymerase |
4 % |
| 7-2-RNP (To) |
Rare |
| NOR (NOR-90) |
Rare |
Mixed Connective Tissue Disease
| 自體抗體 |
盛行率 |
| U1-NRNP |
95-100 % |
| SSDNA |
20-50 % |
Rheumatoid Arthritis
| 自體抗體 |
盛行率 |
| Histone |
Rare |
| ssDNA |
8% |
| Rheumatoid factor |
65-95 % |
| CCP(Filaggrin eptopes) |
80 % |
Progressive Systemic Sclerosis (limited form)
| 自體抗體 |
盛行率 |
| Centromere |
80-95 % |
Neonatal Lupus Erythematosus
Polymary Sjorgren' s Syndrome
| 自體抗體 |
盛行率 |
| SS-A |
40-95 % |
| SS-B |
40-95 % |
| SSDNA |
30-60 % |
| RANA |
70 % |
| Salivary gland excretory ducts |
40-60 % |
| Rheumatoid factors |
60-80 % |
Polymyositis and Dermatomytosi tis
| 自體抗體 |
盛行率 |
| PM-Scl |
8 % |
| Jo-1 |
25 - 35 % |
| Mi-2 |
5 % |
| Ku |
30 - 55 % |
| ss-DNA |
40 - 50 % |
| PL-7. PL-12 |
3-4 % |
| SRP |
Rare |
Chronic Active Autoimmune Hepatitis
| 自體抗體 |
盛行率 |
| Actin |
40 - 90 % |
| ANA (lamins, SS-A and others) |
30 - 40 % |
| Liver-Kidney microsomes (LKM-1) |
7 % |
| Soluble liver Ag/ Liver-pancreas Ag (SLA-LP) |
10-30 % |
| Liver membrane Ag (LMA) |
35 -100 % |
| Liver-specific protein (LSP) |
50 -100 % |
| M2 (pyruvate dehydrogenase) |
5-20 % |
| M9 (glycogen phosphorylase) |
10 % |
| Asialoglyprotein receptor protein |
80 - 90 % |
Primary Biliary Cirrhosis
| 自體抗體 |
盛行率 |
| M2 (pyruvate dehydrogenase) |
95 % |
| M9 (sulfite oxidase) |
Up to 55 % |
| M8 |
Up to 55 % |
| M9 |
35 - 85 % |
| Nuclear dots |
30 % |
| Lamins |
2 % |
Medication-Induced Lupus
| 自體抗體 |
盛行率 |
| Histones |
95 % |
| Ss-DNA |
80 % |